
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


CytoMed Therapeutics Limited Ordinary Shares (GDTC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GDTC (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5
1 Year Target Price $5
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.1% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.47M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.37 | 52 Weeks Range 1.20 - 4.05 | Updated Date 08/29/2025 |
52 Weeks Range 1.20 - 4.05 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -530.32% |
Management Effectiveness
Return on Assets (TTM) -17.44% | Return on Equity (TTM) -24.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19961332 | Price to Sales(TTM) 46.62 |
Enterprise Value 19961332 | Price to Sales(TTM) 46.62 | ||
Enterprise Value to Revenue 369.21 | Enterprise Value to EBITDA -4.45 | Shares Outstanding 11733700 | Shares Floating 3593787 |
Shares Outstanding 11733700 | Shares Floating 3593787 | ||
Percent Insiders 68.86 | Percent Institutions 0.43 |
Upturn AI SWOT
CytoMed Therapeutics Limited Ordinary Shares

Company Overview
History and Background
CytoMed Therapeutics Limited is a Singapore-based biopharmaceutical company focused on the development of novel cell-based immunotherapies for the treatment of cancer. Founded in 2018, it leverages proprietary technologies to engineer and enhance natural killer (NK) cells and T cells for improved therapeutic efficacy. They primarily focus on advancing their pipeline of CAR-NK and TCR-T cell therapies.
Core Business Areas
- Cell-Based Immunotherapies: Focuses on developing CAR-NK and TCR-T cell therapies for cancer treatment. This includes research, development, and clinical trials.
- Proprietary Technologies: Developing and refining technologies for cell engineering and enhancement to improve therapeutic outcomes.
Leadership and Structure
Dr. Tan Wee Kiat is the CEO. The organizational structure consists of research and development, clinical operations, and business development teams.
Top Products and Market Share
Key Offerings
- CAR-NK Cell Therapy (CNK101): A cell-based immunotherapy targeting solid tumors. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include Nkarta and Century Therapeutics
- TCR-T Cell Therapy (CBT201): A cell-based immunotherapy targeting T cell lymphomas. Currently in preclinical development. Market share is not yet applicable as the product is not yet approved. Competitors include Atara Biotherapeutics.
Market Dynamics
Industry Overview
The cell-based immunotherapy market is rapidly growing, driven by advances in cancer treatment. It's characterized by high innovation, competition, and regulatory scrutiny.
Positioning
CytoMed is positioned as a company specializing in NK cell and T cell therapies, leveraging proprietary technologies to improve efficacy and safety. They are aiming to address unmet needs in solid tumors and hematological malignancies.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach billions of USD. CytoMed aims to capture a segment of this market by developing innovative cell therapies for specific cancer indications.
Upturn SWOT Analysis
Strengths
- Proprietary cell engineering technologies
- Experienced leadership team
- Focus on innovative cell therapies
- Pipeline of CAR-NK and TCR-T cell therapies
Weaknesses
- Limited financial resources compared to larger competitors
- Early stage of clinical development
- Reliance on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Advancements in cell therapy technologies
Threats
- Regulatory hurdles
- Competition from established players
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- NKarta (NKTX)
- Atara Biotherapeutics (ATRA)
- Century Therapeutics (IPSC)
Competitive Landscape
CytoMed competes with other companies developing cell-based immunotherapies. Advantages include proprietary technologies and focus on specific cancer targets. Disadvantages include limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of R&D activities, preclinical studies, and initiation of clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates will vary significantly based on the progress of their pipeline.
Recent Initiatives: Recent initiatives include advancing CNK101 in clinical trials and expanding the TCR-T cell therapy platform.
Summary
CytoMed Therapeutics Limited is a promising but still early-stage biopharmaceutical company focused on developing novel cell therapies. They possess proprietary technology and are working on a focused pipeline. Success hinges on positive clinical trial results and securing funding. They need to be aware of stiff competition and stringent regulatory requirements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytoMed Therapeutics Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://w2.cytomed.sg |
Full time employees 43 | Website https://w2.cytomed.sg |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.